配伍对珠子参中4个皂苷类成分药代动力学的影响  

Effect of Compatibility on Pharmacokinetics of Four Saponins in Panacis Majoris Rhizoma

作　　者：王小平[1] 白吉庆[1] 王亚恒[1] 王金[1] 胡锦萍[1] 权利娜[1] 黎丹[1] 王芳[1] 叶峥嵘[1] 沈舒文[1] 

机构地区：[1]陕西中医药大学,陕西咸阳712046

出　　处：《中国实验方剂学杂志》2017年第6期111-116,共6页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：陕西省科技厅项目(2012KTCL03-14);陕西省科技厅中药现代化项目[2009K19-03(2)]

摘　　要：目的:研究不同配伍对藤珠胃康方中臣药珠子参主要成分在大鼠体内的药代动力学影响,为该复方的研究与开发提供参考。方法:将SD大鼠随机分为珠子参组、珠子参-藤梨根组、珠子参-白术组、珠子参-黄精组、珠子参-三棱组、藤珠胃康方组,灌服给药剂量均为10.0 g·kg^(-1)(按生药量计算),采用HPLC检测0~24 h大鼠血浆中人参皂苷Re,人参皂苷Rb1,人参皂苷Ro和竹节参皂苷Ⅳa的血药浓度,流动相乙腈(A)-0.02%磷酸水溶液(B)梯度洗脱(0~14 min,19%~26%A;14~22 min,26%~29%A;22~30 min,29%A;30~40 min,29%~35%A;40~55 min,35%A),检测波长205 nm,运用DAS 3.0软件计算药代动力学参数,比较不同配伍对珠子参中4个指标成分的药动学差异。结果:与珠子参组比较,珠子参-藤梨根组、珠子参-黄精组、珠子参-白术组、珠子参-三棱组中人参皂苷Re,人参皂苷Rb1,人参皂苷Ro和竹节参皂苷Ⅳa的药峰浓度(Cmax)和药时曲线下面积(AUC0-t)大部分增加,清除率/生物利用度(CL/F)降低;而藤珠胃康方组中上述4个成分的Cmax和AUC0-t增加,CL/F降低。与珠子参组相比,藤珠胃康方中主要成分代谢显著减慢,4个皂苷类成分的血药浓度明显提高。结论:不同配伍会影响珠子参主要药效成分在体内的药代动力学参数,为藤珠胃康方的临床应用提供参考依据。Objective： To investigate effect of different compatibility on pharmacokinetics in rats of main components in Panacis Majoris Rhizoma from Tengzhu Weikang prescription after oral administration. Method： SD rats were randomly divided into Panacis Majoris Rhizoma（ PMR） group,PMR-Actinidia chinensis（ AC） group,PMR-Atractylodis Macrocephalae Rhizoma（ AMR） group,PMR-Polygonati Rhizoma（ PR） group,PMR-Sparganii Rhizoma（ SR） group and Tengzhu Weikang prescription group. After oral administration with dosage of10. 0 g·kg^-1,HPLC was employed with the mobile phase of acetonitrle-0. 02% phosphoric acid aqueous solution for gradient elution and detection wavelength at 205 nm. The pharmacokinetic parameters of ginsenoside Re,ginsenoside Rb1,ginsenoside Ro and chikusetsusaponin Ⅳ a were calculated by DAS 3. 0 software. Result：Compared with PMR group,most of PMR-AC group,PMR-AMR group,PMR-PR group,PMR-SR group and Tengzhu Weikang prescription group showed a higher Cmaxand AUC0-tfor ginsenoside Re, ginsenoside Rb1,ginsenoside Ro and chikusetsusaponin Ⅳ a, and all showed a lower clearance rate / bioavailability（ CL / F）.Compared with PMR group, Tengzhu Weikang prescription group showed slower metabolism and higher plasma concentration of ginsenoside Re, ginsenoside Rb1,ginsenoside Ro and chikusetsusaponin Ⅳ a. Conclusion：Different compatibility has effect on pharmacokinetic parameters of main efficacy components in PMR from Tengzhu Weikang prescription.

关 键 词：藤珠胃康方 珠子参 人参皂苷RE 人参皂苷RB1 人参皂苷Ro 竹节参皂苷Ⅳa 配伍 药动学 

分 类 号：R969.1[医药卫生—药理学] R284.1[医药卫生—药学]